---
company: BALCHEM CORP
ticker: BCPC
form: 8-K
filed: 2026-07-31
accession: 0000009326-26-000026
source: https://www.sec.gov/Archives/edgar/data/9326/000000932626000026/
---

# Balchem (BCPC) earnings release, July 31, 2026

Balchem Corp (BCPC) · Form 8-K, Item 2.02 · Filed 2026-07-31 · [SEC filing](https://www.sec.gov/Archives/edgar/data/9326/000000932626000026/)

Balchem Corporation Reports Second Quarter 2026 Financial Results

Montvale, NJ, July 31, 2026

- Balchem Corporation (NASDAQ: BCPC) today reported financial results for its 2026 fiscal second quarter ended June 30, 2026. For the quarter, the Company reported net sales of $284.0 million, net earnings of $44.6 million, adjusted EBITDA

(a) of $77.9 million, and free c ash flow

(a) of $36.2 million.

Ted Harris, Chairman, President and CEO of Balchem, said, “The second quarter was another very strong quarter for Balchem with healthy growth in all three of our reporting segments. On a consolidated basis, we delivered record quarterly net sales, net earnings, and adjusted EBITDA, as well as solid cash flows.”

Second Quarter 2026 Financial Highlights:

• Net sales were $284.0 million, an increase of 11.2% from the prior year quarter.

• GAAP net earnings were $44.6 million, an increase of 16.6% from the prior year quarter.

• Adjusted EBITDA was $77.9 million, an increase of 12.6% from the prior year quarter.

• GAAP earnings per share were $1.39 compared to $1.17 in the prior year quarter and adjusted earnings per share

(a) were $1.49 compared to $1.27 in the prior year quarter.

• Cash flows from operations were $46.7 million, with free cash flow

(a) of $36.2 million.

• Excellent sales and earnings from operations growth in all three of our reporting segments.

Recent Highlights:

• On July 24, 2026, we entered into an amendment to our existing credit agreement, that was due July 27, 2027, with lenders in the form of a senior secured revolving credit facility, now due July 24, 2031. This amendment increased the allowed borrowing from $550 million to $650 million, and expanded the company's ability to fund growth, innovation, and acquisitions.

• Balchem repurchased $29 million of common stock during the second quarter and $114 million over the trailing twelve months, reflecting the Company's balanced capital allocation strategy and commitment to long-term shareholder value creation.

Mr. Harris said, “I am extremely pleased with our second quarter financial performance and the strong execution around our strategic priorities across our businesses.”

Mr. Harris added, “These excellent first half of 2026 results continue the strong growth momentum we have built over the years and we remain excited about the future outlook of our company.”

Balchem Corporation (NASDAQ:BCPC)

Results for Period Ended June 30, 2026 (unaudited)

(Dollars in thousands, except per share data)

Balchem Corporation (NASDAQ:BCPC)

Financial Results for the Second Quarter of 2026:

The

Human Nutrition and Health segment generated record quarterly sales of $176.9 million, an increase of $16.1 million, or 10.0%, compared to the prior year quarter. The increase was driven by higher sales within both the nutrients business and the food ingredients and solutions businesses. Record earnings from operations for this segment of $42.4 million increased $4.0 million, or 10.5%, compared to $38.3 million in the prior year quarter, primarily due to the aforementioned higher sales and favorable mix, partially offset by certain higher manufacturing input costs and higher operating expenses. Excluding the effect of non-cash expense associated with amortization of acquired intangible assets and other adjustments, record adjusted earnings from operations

(a) for this segment were $45.9 million, compared to $41.4 million in the prior year quarter, an increase of 10.9%.

The

Animal Nutrition and Health segment generated quarterly sales of $64.5 million, an increase of $8.4 million, or 15.0%, compared to the prior year quarter. The increase was driven by higher sales in both the monogastric and ruminant species markets. Second quarter earnings from operations for this segment of $5.2 million increased $1.7 million, or 48.7%, compared to $3.5 million in the prior year quarter, primarily due to the aforementioned higher sales, partially offset by certain higher manufacturing input costs and higher operating expenses. Excluding the effect of non-cash expense associated with amortization of acquired intangible assets and other adjustments, adjusted earnings from operations for this segment were $5.6 million compared to $3.8 million in the prior year quarter, an increase of 47.7%.

The

Specialty Products segment generated record quarterly sales of $40.5 million, an increase of $3.3 million, or 8.9%, compared to the prior year quarter, due to higher sales in both the performance gases and plant nutrition businesses. Record earnings from operations for this segment of $12.9 million increased $1.6 million, or 14.4%, compared to $11.3 million in the prior year quarter, primarily driven by the aforementioned higher sales and favorable mix, partially offset by certain higher manufacturing input costs and higher operating expenses. Excluding the effect of non-cash expense associated with amortization of acquired intangible assets and other adjustments, record adjusted earnings from operations for this segment were $13.9 million, compared to $12.4 million in the prior year quarter, an increase of 12.1%.

Record consolidated quarterly gross margin of $103.7 million increased by $10.6 million, or 11.4%, compared to $93.1 million for the prior year comparable period. Gross margin as a percentage of sales was 36.5% compared to 36.4% in the prior year period, an increase of 10 basis points, primarily due to sales growth and manufacturing efficiencies, partially offset by certain higher manufacturing input costs. Operating expenses of $44.5 million for the quarter increased $2.8 million from the prior year comparable quarter, primarily due to higher compensation-related costs.

Net interest expense was $1.9 million and $2.8 million in the second quarters of 2026 and 2025, respectively.

The decrease in interest expense was primarily due to lower outstanding borrowings and lower interest rates.... (truncated)d 2025 were

22.8% a nd 21.9%, respectively. The increase in the effective tax rate was primarily due to lower tax benefits from stock-based compensation.

Second quarter cash flows provided by operating activities were $46.7 million and free cash flow was $36.2 million. Net working capital of $242.7 million as of June 30, 2026 included a cash balance of $63.2 million. Significant cash payments during the quarter included repurchases of common stock of $28.8 million, income taxes paid of $27.8 million, net debt payments of $17.0 million, and capital expenditures and intangible assets acquired of $10.9 million. Outstanding debt on our revolving loan was $152.0 million as of June 30, 2026 and our net debt

(b) was $88.8 million, with an overall leverage ratio

(c) on a net debt basis of 0.3 times.

Ted Harris said, “The Balchem team delivered another strong quarter in Q2 of 2026, and we remain confident in the long-term growth outlook for our company as we continue to execute our strategic growth initiatives.”

Balchem Corporation (NASDAQ:BCPC)

Quarterly Conference Call

A quarterly conference call will be held on Friday, July 31, 2026, at 11:00 AM Eastern Time (ET) to review second quarter 2026 results. Ted Harris, Chairman, President and CEO and Martin Bengtsson, CFO will host the call. Institutional investors, analysts and other members of the financial community are invited to join the live call by dialing +1-833-461-5787 (USA/Canada toll free) or +1-585-542-9983 (International Toll), and referencing Meeting ID: 980453675, five minutes prior to the scheduled start time of the conference call. Investors and the public are invited to listen to the live webcast at https://events.q4inc.com/attendee/980453675. The conference call will be available for replay shortly after the conclusion of the call at https://events.q4inc.com/attendee/980453675 for one year.

Segment Information

Balchem Corporation reports three business segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition and Health segment delivers customized food and beverage ingredient systems, as well as key nutrients into a variety of applications across the food, supplement and pharmaceutical industries. The Animal Nutrition and Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged performance gases for use in healthcare and other industries, and also provides chelated minerals to the micronutrient agricultural market. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated".

Forward-Looking Statements

This release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, which reflect our expectation or belief concerning future events that involve risks and uncertainties. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "forecast," "outlook," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," or the negative thereof or variations thereon or similar expressions generally intended to identify forward-looking statements. Forward-looking statements may relate to such matters as projections of revenue, margins, expenses, tax provisions, earnings, cash flows, benefit obligations, dividends, share repurchases or other financial items; any statements of the plans, strategies and objectives of management for future operations, including those relating to any statements concerning expected development, performance or market share relating to our products and services; any statements regarding future economic conditions or our performance; any statements regarding pending investigations, claims or disputes; any statements of expectation or belief; and any statements of assumptions underlying any of the foregoing. These statements are based on the Company's currently available information and our current assumptions, expectations and projections about future events. They are subject to future events, risks and uncertainties - many of which are beyond the Company’s control - as well as potentially inaccurate assumptions, that could cause actual results to differ materially from those in the forward-looking statements. Important factors and other risks that may affect the Company's business or that could cause actual results to differ materially are included in filings the Company makes with the U.S. Securities and Exchange Commission from time to time, including its Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, its Current Reports on Form 8-K, and in its other SEC filings. Reference should be made to such factors and all forward-looking statements are qualified in their entirety by the above cautionary statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact: Jacqueline Yarmolowicz, Balchem Corporation (Telephone: 845-326-5600)

Balchem Corporation (NASDAQ:BCPC)

Selected Financial Data (unaudited)

($ in 000’s)

Balchem Corporation (NASDAQ:BCPC)

Balchem Corporation (NASDAQ:BCPC)

Balchem Corporation

Condensed Consolidated Statements of Cash Flows

(Dollars in thousands)

(unaudited)

Balchem Corporation (NASDAQ:BCPC)

Non-GAAP Financial Information... (truncated)results. The non-GAAP financial measures in this press release include adjusted gross margin, adjusted earnings from operations, adjusted net earnings and the related adjusted diluted per share amounts, EBITDA, adjusted EBITDA, adjusted income tax expense, free cash flow, net debt, and leverage ratio. The non-GAAP financial measures disclosed by the Company exclude certain business combination accounting adjustments and certain other items related to acquisitions, certain equity compensation, nonqualified deferred compensation plan expense (income), and certain one-time or unusual transactions. Detailed non-GAAP adjustments are described in the reconciliation tables below and also explained in the related footnotes. These non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations from these results should be carefully evaluated. Investors should not consider non-GAAP measures as alternatives to the related GAAP measures.

Set forth below are reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.

Table 1

(unaudited)

Reconciliation of Non-GAAP Measures to GAAP

(Dollars in thousands, except per share data)

Balchem Corporation (NASDAQ:BCPC)

Table 2

(unaudited)

Reconciliation of GAAP Net Earnings to EBITDA and to Adjusted EBITDA

(Dollars in thousands)

Table 3

(unaudited)

Reconciliation of GAAP Effective Income Tax Rate to Non-GAAP Effective Income Tax Rate

(Dollars in thousands)

Balchem Corporation (NASDAQ:BCPC)

Table 4

(unaudited)

Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow

(Dollars in thousands)

## Financial statements

### Income Statement (Three Months Ended June 30, — (Dollars in thousands, except per share data))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Net sales | 283,997 | 255,467 | 554,706 | 505,986 |
| Gross margin | 103,683 | 93,113 | 204,767 | 181,281 |
| Operating expenses | 44,462 | 41,671 | 89,920 | 78,824 |
| Earnings from operations | 59,221 | 51,442 | 114,847 | 102,457 |
| Interest and other expenses | 1,440 | 2,431 | 4,544 | 5,506 |
| Earnings before income tax expense | 57,781 | 49,011 | 110,303 | 96,951 |
| Income tax expense | 13,166 | 10,733 | 25,403 | 21,620 |
| Net earnings | 44,615 | 38,278 | 84,900 | 75,331 |
| Diluted net earnings per common share | 1.39 | 1.17 | 2.63 | 2.3 |
| Adjusted EBITDA(a) | 77,943 | 69,224 | 152,225 | 135,514 |
| Adjusted net earnings(a) | 48,096 | 41,561 | 91,087 | 81,578 |
| Adjusted net earnings per common share(a) | 1.49 | 1.27 | 2.83 | 2.49 |
| Shares used in the calculations of diluted and adjusted net earnings per common share | 32,200 | 32,682 | 32,242 | 32,744 |

### Income Statement (Three Months Ended June 30, — (Dollars in thousands))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Net earnings - as reported | 44,615 | 38,278 | 84,900 | 75,331 |
| Add back: | Provision for income taxes | 13,166 | 10,733 | 25,403 | 21,620 |
| Add back: | Interest and other expenses | 1,440 | 2,431 | 4,544 | 5,506 |
| Add back: | Depreciation and amortization | 12,148 | 11,330 | 24,567 | 22,272 |
| Add back: | EBITDA | 71,369 | 62,772 | 139,414 | 124,729 |
| Add back: | Non-cash compensation expense related to equity awards | 5,921 | 5,838 | 11,277 | 9,648 |
| Add back: | Transaction and integration costs (2) | 22 | 405 | 917 | 894 |
| Add back: | Nonqualified deferred compensation plan expense (3) | 631 | 401 | 617 | 435 |
| Add back: | Restructuring costs (4) |  | -192 |  | -192 |
| Add back: | Adjusted EBITDA | 77,943 | 69,224 | 152,225 | 135,514 |

### Income Statement (Three Months Ended June 30, — (Dollars in thousands))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – Effective Tax Rate | Three Months Ended June 30, – 2025 | Three Months Ended June 30, – Effective Tax Rate |
|---|---:|---:|---:|---:|
| GAAP Income Tax Expense | 13,166 | 22.8 | 10,733 | 21.9 |
| Impact of ASU 2016-09 (6) | -24 |  | 283 |  |
| Adjusted Income Tax Expense | 13,142 | 22.7 | 11,016 | 22.5 |

### Income Statement (Six Months Ended June 30, — (Dollars in thousands))

| | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – Effective Tax Rate | Six Months Ended June 30, – 2025 | Six Months Ended June 30, – Effective Tax Rate |
|---|---:|---:|---:|---:|
| GAAP Income Tax Expense | 25,403 | 23 | 21,620 | 22.3 |
| Impact of ASU 2016-09 (6) | 1,290 |  | 873 |  |
| Adjusted Income Tax Expense | 26,693 | 24.2 | 22,493 | 23.2 |

### Balance Sheet (Selected Balance Sheet Items — Balchem Corporation (NASDAQ:BCPC) (in thousands))

| | June 30, 2026 – (unaudited) | December 31, 2025 |
|---|---:|---:|
| Cash and cash equivalents | 63,174 | 74,570 |
| Accounts receivable, net | 148,973 | 143,596 |
| Inventories | 161,551 | 131,449 |
| Other current assets | 14,726 | 15,999 |
| Total current assets | 388,424 | 365,614 |
| Property, plant and equipment, net | 304,702 | 306,648 |
| Goodwill | 808,809 | 816,375 |
| Intangible assets with finite lives, net | 151,643 | 163,289 |
| Right of use assets | 14,120 | 16,192 |
| Other assets | 19,306 | 18,134 |
| Total non-current assets | 1,298,580 | 1,320,638 |
| Total assets | 1,687,004 | 1,686,252 |
| Current liabilities | 145,755 | 176,384 |
| Revolving loan | 152,000 | 164,000 |
| Deferred income taxes | 52,943 | 54,143 |
| Other long-term obligations | 33,928 | 34,312 |
| Total liabilities | 384,626 | 428,839 |
| Stockholders' equity | 1,302,378 | 1,257,413 |
| Total liabilities and stockholders' equity | 1,687,004 | 1,686,252 |

### Cash Flow (Six Months Ended June 30, — (unaudited))

| | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|
| Cash flows from operating activities: | Net earnings | 84,900 | 75,331 |
| Adjustments to reconcile net earnings to net cash provided by operating activities: | Depreciation and amortization | 24,711 | 22,417 |
| Adjustments to reconcile net earnings to net cash provided by operating activities: | Stock compensation expense | 11,277 | 9,648 |
| Adjustments to reconcile net earnings to net cash provided by operating activities: | Other adjustments | 1,100 | -1,192 |
| Adjustments to reconcile net earnings to net cash provided by operating activities: | Changes in assets and liabilities | -35,216 | -22,495 |
| Adjustments to reconcile net earnings to net cash provided by operating activities: | Net cash provided by operating activities | 86,772 | 83,709 |
| Cash flows from investing activities: | Capital expenditures and intangible assets acquired | -17,138 | -12,372 |
| Cash flows from investing activities: | Cash paid for acquisitions, net of cash acquired |  | -323 |
| Cash flows from investing activities: | Proceeds from the sale of assets | 7 | 267 |
| Cash flows from investing activities: | Investment in affiliates | -95 | -105 |
| Cash flows from investing activities: | Net cash used in investing activities | -17,226 | -12,533 |
| Cash flows from financing activities: | Proceeds from revolving loan | 80,000 | 63,000 |
| Cash flows from financing activities: | Principal payments on revolving loan | -92,000 | -63,000 |
| Cash flows from financing activities: | Principal payments on finance leases | -102 | -97 |
| Cash flows from financing activities: | Proceeds from stock options exercised | 7,742 | 6,222 |
| Cash flows from financing activities: | Dividends paid | -30,772 | -28,265 |
| Cash flows from financing activities: | Repurchases of common stock | -44,484 | -38,589 |
| Cash flows from financing activities: | Net cash used in financing activities | -79,616 | -60,729 |
| Cash flows from financing activities: | Effect of exchange rate changes on cash | -1,326 | 5,465 |

### Cash Flow (Three Months Ended June 30, — (Dollars in thousands))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Net cash provided by operating activities | 46,711 | 47,252 | 86,772 | 83,709 |
| Capital expenditures and proceeds from the sale of assets | -10,480 | -6,554 | -16,696 | -11,975 |
| Free cash flow | 36,231 | 40,698 | 70,076 | 71,734 |
